Anbio Biotechnology Class A Ordinary Shares
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Anbio Biotechnology (NNNN) develops and provides innovative in vitro diagnostics (IVD) products for over-the-counter (OTC), point-of-care testing (POCT), laboratory, wellness, and at-home applications; its core offerings encompass five platforms including Chemiluminescence Immunoassay (ChLIA) with dry chemistry solutions such as the ADL-1000 analyzer, Lateral Flow Immunoassay (LFIA or colloidal gold), Fluorescent Immunoassay (FIA) with portable analyzers supporting up to 83 assays, Polymerase Chain Reaction (RT-PCR) with 25 laboratory assays, and Loop-mediated Isothermal Amplification (LAMP) for nucleic acid detection; these detect biomarkers across infectious diseases (65 assays including SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B tests), cancer (34 assays), cardiovascular conditions (23-32 assays), hormones (36 assays), inflammation (9 assays), drugs of abuse (37 assays), pharmacogenomics, endocrine disorders, renal disease, and diabetes, compatible with sample types such as serum, plasma, whole blood, feces, urine, and saliva. The company, incorporated in 2021 and headquartered in Frankfurt am Main, Germany, operates in the European Union, Asia Pacific, North America, South America, Africa, and internationally, serving healthcare providers, patients, and veterinary markets with additional offerings in fertility, cardiac markers, thyroid hormones, immunological functions, and veterinary infectious diseases. Recent developments include a strategic expansion into point-of-care diagnostics with over 300 assays emphasizing dry reagent technology for sustainability and reduced testing time by 40 percent, diversification from pandemic-era tests (now 56 percent of revenue from oncology, cardiovascular, and other infectious assays despite a 36 percent revenue decline in 2025), an initial public offering raising $8 million to fund R&D and market access, participation in key 2025 events such as CACLP in Hangzhou and MEDLAB Middle East with new product showcases, and ongoing IVDR regulatory preparedness in the EU amid competition from Roche and Abbott.
Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review
Head-To-Head Contrast: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)
Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)
Financial Comparison: Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX)
Analyzing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)
Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Financial Comparison
Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)
Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN) Critical Analysis
Reviewing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)
Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Critical Comparison
Head to Head Contrast: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)
Analyzing Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)
Critical Survey: Anbio Biotechnology (NASDAQ:NNNN) versus Oncocyte (NASDAQ:IMDX)
Head-To-Head Survey: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)
Contrasting Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)
Reviewing Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)
Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Financial Contrast
Anbio Biotechnology (NASDAQ:NNNN) vs. Oncocyte (NASDAQ:IMDX) Head-To-Head Review
Head-To-Head Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)
Head to Head Comparison: Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX)